Page 84 - 87_04

5. Feik SA, Thomas CD, Clement JG. Age-related changes in cortical po-
rosity of the midshaft of the human femur. J Anat 1997;191: 407-
416.
6. Schaadt O, Bohr H. Different trends of age-related diminution of
bone mineral content in the lumbar spine, femoral neck, and femoral
shaft in women. Calcif Tissue Int 1988;42: 71-76.
7. Frost HM. Wolff's Law and bone's structural adaptations to mecha-
nical usage: an overview for clinicians. The Angle Orthodontist 1994; 21. Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts.
64: 175–188.
8. Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev
Physiol 2020; 82: 485–506.
9. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;
289:1504-1508.
10. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling
and remodeling. Arch Biochem Biophys. 2008; 473: 139–146.
11. Watts NB, Diab DL Long-term use of bisphosphonates in osteoporosis.
J Clin Endocrinol Metab 2010; 95: 1555–1565.
12. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of ac-
tion and role in clinical practice. Mayo Clin Proc 2008 83: 1032–
1045.
13. Portal-Núñez S, Mediero A, Esbrit P, Sánchez-Pernaute O, Largo R,
Herrero-Beaumont G. Unexpected bone formation produced by
RANKL blockade. Trends Endocrinol Metab 2017; 28: 695-704.
14. Harman D. Origin and evolution of the free radical theory of aging:
a brief personal history, 1954-2009. Biogerontology 2009;10: 773-
781.
15. Portal-Núñez S, Lozano D, de la Fuente M, Esbrit P. Pathophysiology
of aging bone. Rev Esp Geriatr Gerontol 2012;47: 125-131.
16. Martínez ME, del Campo MT, Medina S, Sánchez M, Sánchez-Cabe-
zudo MJ, Esbrit P, Martínez P, Moreno I, Rodrigo A, Garcés MV, Mu-
nuera L. Influence of skeletal site of origin and donor age on
osteoblastic cell growth and differentiation. Calcif Tissue Int 1999;
64: 280-286.
17. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas
SC. Increased bone formation by prevention of osteoblast apoptosis
with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
18. Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein
RS, manolagas SC. Decreased oxidative stress and greater bone ana-
bolism in the aged, when compared to the young, murine skeleton
with parathyroid hormone administration. Aging Cell 2010; 9: 851–
867.
19. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas
T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alen-
dronate for fracture prevention in women with osteoporosis. N Engl
J Med 2017; 377:1417-1427.
Use of peptides derived from parathyroid hormone-related protein
442 for increasing bone formation and bone regeneration
Pedro Esbrit Argüelles
An. Real Acad. Farm. Vol. 87. Nº 4 (2021) · pp.433-443
ANALES
RANF
www.analesranf.com
20. Esbrit P, Alcaraz MJ. Current perspectives on parathyroid hormone
(PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
Biochem Pharmacol 2013; 85:1417–1423.
Cell Signal 2009;21: 245–254.
22. Miao D, He B, Jiang Y, Kobayashi T, Sorocéanu MA, Zhao J, Su H,
Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman
D, Karaplis AC. Osteoblast-derived PTHrP is a potent endogenous
bone anabolic agent that modifies the therapeutic efficacy of admi-
nistered PTH 1–34. J Clin Invest. 2005;115: 2402-2411.
23. Martínez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martínez ME.
Age-related changes in parathyroid hormone-related protein and
vascular endothelial growth factor in human osteoblastic cells. Os-
teoporosis Int 2002; 13: 874-881.
24. Portal-Núñez S, Manassra R, Lozano D, Acitores A, Mulero F, Villa-
nueva-Peñacarrillo ML, De la Fuente M, Esbrit P. Characterization of
skeletal alterations in a model of prematurely aging mice. Age 2013;
35: 383-393.
25. Horwitz MJ, Augustine M, Kahn L, Martin E, Oakley CC, Carneiro RM,
Tedesco MB, Laslavic A, Sereika SM, Bisello A, García-Ocaña A,
Gundberg CM, Cauley JA, Stewart AF (2013) A comparison of pa-
rathyroid hormone-related protein (1-36) and parathyroid hormone
(1-34) on markers of bone turnover and bone density in postmeno-
pausal women: the PrOP study. J Bone Miner Res 28:2266–2276.
26. Esbrit P, Portal-Núñez S, Herrera S, Nogués X, Díez-Pérez A. Parathy-
roid hormone-related protein analogues as osteoporosis therapies.
Calcif Tissue Int 2016; 98: 359-369.
27. Ardura JA, Portal-Núñez S, Alonso V, Bravo B, Gortázar AR. Handling
parathormone receptor type 1 in skeletal diseases: realities and ex-
pectations of abaloparatide. Trends Endocrinol Metab 2019; 30:
756-766.
28. Cornish J, Callon KE, Nicholson GC, Reid IR. Parathyroid hormone-
related protein-(107-139) inhibits bone resorption in vivo. Endocri-
nology 1997; 138: 1299–1304.
29. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR. Stimulation
of osteoblast proliferation by C-terminal fragments of parathyroid
hormone-related protein. J Bone Miner Res 1999;14: 915–922.
30. Miao D, Su H, He B, Gao J, Xia Q, Zhu M, Gu Z, Goltzman D, Karaplis
AC. Severe growth retardation and early lethality in mice lacking the
nuclear localization sequence and C-terminus of PTH-related protein.
Proc Natl Acad Sci USA 2008; 105: 20309-20314.
31. de Castro LF, Lozano D, Portal-Núñez S, Maycas M, De la Fuente M,
Caeiro JR,et al. Comparison of the skeletal effects induced by daily
administration of PTHrP (1-36) and PTHrP (107-139) to ovariecto-
mized mice. J Cell Physiol 2012; 227: 1752–1760.